Short Interest in AstraZeneca PLC (OTCMKTS:AZNCF) Drops By 41.9%

AstraZeneca PLC (OTCMKTS:AZNCF) was the recipient of a significant drop in short interest in the month of June. As of June 15th, there was short interest totalling 12,200 shares, a drop of 41.9% from the May 31st total of 21,000 shares. Based on an average trading volume of 3,600 shares, the short-interest ratio is presently 3.4 days.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in AstraZeneca stock. Kennedy Capital Management LLC purchased a new stake in AstraZeneca PLC (OTCMKTS:AZNCF) during the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm purchased 37,554 shares of the company’s stock, valued at approximately $5,068,000. 40.87% of the stock is currently owned by institutional investors and hedge funds.

AstraZeneca Trading Down 1.5 %

Shares of AZNCF opened at $156.27 on Friday. The business’s fifty day moving average is $154.02 and its 200 day moving average is $139.96. AstraZeneca has a 12-month low of $118.16 and a 12-month high of $162.00.

AstraZeneca Company Profile

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company's marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.